For laboratory research use only. Not for human or veterinary use. Read our research-use policy

Research peptides

GLP-1 and incretin research peptides

These compounds share one research theme: receptor pharmacology of the incretin, glucagon and amylin systems. Semaglutide acts on the GLP-1 receptor, tirzepatide on the GIP and GLP-1 receptors, survodutide on the glucagon and GLP-1 receptors, retatrutide on all three of the GIP, GLP-1 and glucagon receptors, and cagrilintide on the amylin and calcitonin receptors. Each page below lists the sizes we stock, the identity data, and the primary literature.

Triple GIP, GLP-1 and glucagon receptor agonist peptide

Retatrutide

A synthetic peptide that agonises the glucagon, GIP and GLP-1 receptors (development code LY3437943).

9 sizes · from $17.99

Dual GIP and GLP-1 receptor agonist peptide

Tirzepatide

A 39-amino-acid fatty-diacid-modified peptide that agonises the GIP and GLP-1 receptors (development code LY3298176).

9 sizes · from $16.99

GLP-1 receptor agonist peptide analogue

Semaglutide

A GLP-1 analogue with two amino acid substitutions and a fatty diacid derivatisation at lysine 26.

6 sizes · from $14.99

Long-acting amylin analogue

Cagrilintide

A stable, lipidated, long-acting analogue of the pancreatic hormone amylin that agonises amylin and calcitonin receptors.

2 sizes · from $32.99

Dual glucagon and GLP-1 receptor agonist peptide

Survodutide

A peptide that agonises both the glucagon receptor and the GLP-1 receptor.

1 size · from $69.99

Dual GLP-1 and glucagon receptor agonist peptide

Mazdutide

A once-weekly peptide that agonises both the GLP-1 receptor and the glucagon receptor.

1 size · from $51.99

Related guides

Frequently asked questions

Which receptors do these research peptides act on?

Semaglutide acts on the GLP-1 receptor, tirzepatide on the GIP and GLP-1 receptors, survodutide on the glucagon and GLP-1 receptors, retatrutide on all three of the GIP, GLP-1 and glucagon receptors, and cagrilintide on the amylin and calcitonin receptors.

How is the identity of a batch checked?

By mass spectrometry. PubChem lists semaglutide as C187H291N45O59 and tirzepatide as C225H348N48O68; molecules this size show a series of multiply charged ions. Retatrutide has no PubChem record under that name, so its formula and mass should come from the batch COA.

Do the pages describe clinical results?

The compound pages summarise the published literature with PubMed references, and our library describes clinical trials by design only: who was enrolled, the comparison, the duration and the primary endpoint.

Prices are checked when the site is built; open a compound page for live stock. All research peptides · Full catalog